Veterinary Vaccines and Biologics: Understanding USDA’s Role

Veterinary biologics have their own framework

In the United States, USDA APHIS regulates veterinary biologics such as vaccines, bacterins, antisera and certain diagnostic products under authorities including the Virus-Serum-Toxin Act. The Center for Veterinary Biologics is the key APHIS program for this area.

That creates an early strategic fork for companies working on infectious-disease prevention, immunological products or certain diagnostics. Classification should be resolved before designing a regulatory program.

Product, establishment and manufacturing questions matter

Biologics regulation is not only about whether a vaccine works. Manufacturing facilities, purity, safety, potency, consistency and labeling are part of the system. Development teams therefore need quality and manufacturing expertise early.

Investors should ask whether the company has identified the appropriate U.S. pathway and whether its manufacturing strategy can support the product it intends to commercialize.

Platform technology does not remove product-specific work

A novel vaccine platform can create leverage across indications, but each product still needs a defined target, species, claim, evidence package and manufacturing controls. The platform is commercially valuable when it shortens future development without weakening product-level evidence.

A company that can explain what is reusable across its pipeline—and what must be repeated—offers a more credible view of capital efficiency.

Regulatory conversations reduce expensive assumptions

Early interaction with the responsible agency can clarify classification and study expectations. This is especially important at the border between biologics, drugs, diagnostics and emerging technologies.

The goal is not simply to “have a regulatory plan.” It is to make the scientific development plan produce the evidence the regulator will actually need.